MedTrace Logo

Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects

NCT00987272 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 267

Last updated 2014-07-31

No results posted yet for this study

Summary

The purpose of the study is to demonstrate safety and efficacy of Olopatadine 0.2% compared to its vehicle in Japanese subjects in the treatment of acute allergen-mediated conjunctivitis using the conjunctival allergen challenge (CAC) test.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

Olopatadine Hydrochloride Ophthalmic Solution, 0.2%

DRUG

Olopatadine Hydrochloride Ophthalmic Solution, 0.1%

DRUG

Olopatadine 0.2% Vehicle

Inactive ingredients used as placebo comparator

DRUG

Olopatadine 0.1% Vehicle

Inactive ingredients used as placebo comparator

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Pamela Smith, BS · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2009-11-30
Completion
2009-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00987272 on ClinicalTrials.gov